R. Amrein

2.7k total citations
50 papers, 1.7k citations indexed

About

R. Amrein is a scholar working on Psychiatry and Mental health, Pharmacology and Experimental and Cognitive Psychology. According to data from OpenAlex, R. Amrein has authored 50 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 18 papers in Pharmacology and 11 papers in Experimental and Cognitive Psychology. Recurrent topics in R. Amrein's work include Treatment of Major Depression (15 papers), Electroconvulsive Therapy Studies (10 papers) and Epilepsy research and treatment (10 papers). R. Amrein is often cited by papers focused on Treatment of Major Depression (15 papers), Electroconvulsive Therapy Studies (10 papers) and Epilepsy research and treatment (10 papers). R. Amrein collaborates with scholars based in Switzerland, Brazil and United Kingdom. R. Amrein's co-authors include W. Hetzel, Márcio Versiani, L. J. Thal, Stuart Montgomery, M. Stabl, Antônio Egídio Nardi, F D Mundim, Michael R. Liebowitz, J.G. WHITWAM and Martin Roth and has published in prestigious journals such as Gut, The British Journal of Psychiatry and Psychopharmacology.

In The Last Decade

R. Amrein

50 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Amrein Switzerland	22	592	439	435	269	226	50	1.7k
Thomas L. Schwartz United States	27	689 1.2×	476 1.1×	164 0.4×	360 1.3×	145 0.6×	79	2.3k
L. F. Gram Denmark	26	859 1.5×	1.2k 2.6×	564 1.3×	238 0.9×	235 1.0×	54	3.0k
Tal Burt United States	24	600 1.0×	517 1.2×	203 0.5×	196 0.7×	89 0.4×	48	2.1k
Bruce L. Ehrenberg United States	25	610 1.0×	295 0.7×	315 0.7×	115 0.4×	164 0.7×	46	2.3k
Einat Peles Israel	28	241 0.4×	400 0.9×	348 0.8×	236 0.9×	311 1.4×	109	2.6k
Usoa E. Busto Canada	25	622 1.1×	433 1.0×	948 2.2×	203 0.8×	152 0.7×	42	2.7k
Miriam Adelson Israel	29	319 0.5×	526 1.2×	368 0.8×	272 1.0×	349 1.5×	113	2.9k
Usoa Busto Canada	19	373 0.6×	191 0.4×	323 0.7×	108 0.4×	77 0.3×	28	1.3k
Myroslava K. Romach Canada	24	229 0.4×	305 0.7×	153 0.4×	380 1.4×	162 0.7×	49	1.7k
Paolo Mannelli United States	28	360 0.6×	555 1.3×	139 0.3×	307 1.1×	112 0.5×	91	2.1k

Countries citing papers authored by R. Amrein

Since Specialization

Citations

This map shows the geographic impact of R. Amrein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Amrein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Amrein more than expected).

Fields of papers citing papers by R. Amrein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Amrein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Amrein. The network helps show where R. Amrein may publish in the future.

Co-authorship network of co-authors of R. Amrein

This figure shows the co-authorship network connecting the top 25 collaborators of R. Amrein. A scholar is included among the top collaborators of R. Amrein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Amrein. R. Amrein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nardi, Antônio Egídio, Marina Dyskant Mochcovitch, Rafael C. Freire, et al.. (2015). Prospective, Open, Randomized 3-years Long-term Treatment of Panic Disorder with Clonazepam, Paroxetine, or Their Combination and Follow-up During Additional 6 Years. European Psychiatry. 30. 170–170. 1 indexed citations

Nardi, Antônio Egídio, Sérgio Machado, Flávia Paes, et al.. (2013). Clonazepam for the Treatment of Panic Disorder. Current Drug Targets. 14(3). 353–364. 20 indexed citations

Petitjean, Sylvie, D Ladewig, Christoph Meier, R. Amrein, & Gerhard A. Wiesbeck. (2007). Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. International Clinical Psychopharmacology. 22(5). 292–298. 92 indexed citations

Montgomery, Stuart, L. J. Thal, & R. Amrein. (2003). Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer??s disease. International Clinical Psychopharmacology. 18(2). 61–71. 145 indexed citations

Dingemanse, Jasper, et al.. (1998). Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology. 140(2). 164–172. 18 indexed citations

Versiani, Márcio, R. Amrein, & S.A. Montgomery. (1997). Social phobia. International Clinical Psychopharmacology. 12(5). 239–254. 41 indexed citations

Angst, Jules, R. Amrein, & M. Stabl. (1996). Moclobemide: a paradigm of research in clinical psychopharmacology. International Clinical Psychopharmacology. 11(Supplement 3). 3–7. 3 indexed citations

Groeneweg, Michael, K. Gyr, R. Amrein, et al.. (1996). Effect of flumazenil on the electroencephalogram of patients with portosystemic encephalopathy. Results of a double blind, randomised, placebo-controlled multicentre trial. Electroencephalography and Clinical Neurophysiology. 98(1). 29–34. 19 indexed citations

Meyer, Urs, R. Amrein, L. P. Balant, et al.. (1996). Antidepressants and drug‐metabolizing enzymes — expert group report. Acta Psychiatrica Scandinavica. 93(2). 71–79. 49 indexed citations

10.

Hartmann, D, Andrea M. Cesura, W. Schmid‐Burgk, & R. Amrein. (1995). Relevance of reversible inhibitors of monoamine oxidase type A and of reuptake inhibition for noradrenaline turnover. Acta Psychiatrica Scandinavica. 91(s386). 14–21. 1 indexed citations

11.

WHITWAM, J.G. & R. Amrein. (1995). Pharmacology of flumazenil. Acta Anaesthesiologica Scandinavica. 39(s108). 3–14. 74 indexed citations

12.

Delumeau, Jean-Christophe, Danièle Bentué‐Ferrer, J.M. Gandon, et al.. (1994). Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases. PubMed. 41. 259–266. 18 indexed citations

13.

Moll, Etelka, et al.. (1994). Safety and Efficacy During Long-Term Treatment with Moclobemide. Clinical Neuropharmacology. 17. S74–S87. 19 indexed citations

14.

Amrein, R., W. Hetzel, M. Stabl, & W. Schmid‐Burgk. (1993). RIMA — A new concept in the treatment of depression with moclobemide. International Clinical Psychopharmacology. 7(3). 123–132. 27 indexed citations

15.

Moll, Etelka, et al.. (1992). Long-term treatment with moclobemide. An open-label, non-comparative, multiple-distributed study in patients with a major depressive episode as defined by DSM-III. Psychopharmacology. 106(S1). S120–S122. 8 indexed citations

16.

Gieschke, Ronald, W. Schmid‐Burgk, & R. Amrein. (1988). Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine.. PubMed. 26. 97–104. 16 indexed citations

17.

Amrein, R., et al.. (1987). Flumazenil in Benzodiazepine Antagonism. PubMed. 2(6). 411–429. 73 indexed citations

18.

Amrein, R., et al.. (1980). Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam. European Journal of Clinical Pharmacology. 17(3). 189–196. 29 indexed citations

19.

Priest, R. G., et al.. (1980). Benzodiazepines. 2 indexed citations

20.

Soliva, M., et al.. (1977). Bioavailability from various galenic formulations of flunitrazepam.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 27(12). 2383–8. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact